{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-23-020006","form_type":"8-K","ticker":"PLX","cik":"0001006281","company_name":"Protalix BioTherapeutics, Inc.","filed_at":"2023-12-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:27.821306+00:00","generated_at":"2026-06-07T07:11:53.716539+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Protalix updates on Elfabrio approvals, PRX-115 Phase I progress, and pipeline","bullets":["Elfabrio (Fabry disease) approved by FDA and EMA; launched in US, EU, UK via Chiesi partnership.","Phase I trial of PRX-115 (gout) completed 7th cohort with 56 patients dosed; completion expected Q2 2024.","Preclinical development advancing for PRX-119 (DNase I for NETs-related diseases).","CEO acknowledges ongoing challenges in Israel, reaffirms commitment to operations and pipeline."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-23-020006","json":"https://secwatch.observer/filing/0001558370-23-020006.json","markdown":"https://secwatch.observer/filing/0001558370-23-020006.md","text":"https://secwatch.observer/filing/0001558370-23-020006.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1006281/000155837023020006/0001558370-23-020006-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1006281/000155837023020006/plx-20231226x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T07:11:53.716539+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}